Format

Send to

Choose Destination
Clin Cancer Res. 2017 Nov 1;23(21):6650-6660. doi: 10.1158/1078-0432.CCR-17-0120. Epub 2017 Jul 27.

Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival.

Author information

1
Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
2
MTA TTK Lendület Cancer Biomarker Research Group, Institute of Enzymology, Budapest, Hungary.
3
2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.
4
Department of Medicine, Harvard Medical School, Boston, Massachusetts.
5
Divisions of Hematology/Oncology and Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts.
6
Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.
7
Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
8
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
9
Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
10
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
11
Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois. derekwainwright@northwestern.edu.
12
Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

Abstract

Purpose: Indoleamine 2,3 dioxygenase 1 (IDO1) mediates potent immunosuppression in multiple preclinical models of cancer. However, the basis for elevated IDO1 expression in human cancer, including the most common primary malignant brain tumor in adults, glioblastoma (GBM), is poorly understood. The major objective of this study is to address this gap in our understanding of how IDO1 expression contributes to the biology of GBM, and whether its level of expression is a determinant of GBM patient outcome.Experimental Design: Patient-resected GBM, The Cancer Genome Atlas, human T-cell:GBM cocultures, as well as nu/nu, NOD-scid, and humanized (NSG-SGM3-BLT) mice-engrafted human GBM form the basis of our investigation.Results:In situ hybridization for IDO1 revealed transcript expression throughout patient-resected GBM, whereas immunohistochemical IDO1 positivity was highly variable. Multivariate statistical analysis revealed that higher levels of IDO1 transcript predict a poor patient prognosis (P = 0.0076). GBM IDO1 mRNA levels positively correlated with increased gene expression for markers of cytolytic and regulatory T cells, in addition to decreased patient survival. Humanized mice intracranially engrafted human GBM revealed an IFNγ-associated T-cell-mediated increase of intratumoral IDO1Conclusions: Our data demonstrate that high intratumoral IDO1 mRNA levels correlate with a poor GBM patient prognosis. It also confirms the positive correlation between increased GBM IDO1 levels and human-infiltrating T cells. Collectively, this study suggests that future efforts aimed at increasing T-cell-mediated effects against GBM should consider combinatorial approaches that coinhibit potential T-cell-mediated IDO1 enhancement during therapy. Clin Cancer Res; 23(21); 6650-60. ©2017 AACR.

PMID:
28751450
PMCID:
PMC5850948
[Available on 2018-11-01]
DOI:
10.1158/1078-0432.CCR-17-0120
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center